Medicare will save approximately $12 billion, or 44%, on 15 high-cost medications as a result of the second round of the program’s drug price negotiations, the Trump administration announced Tuesday ...

Major stock indexes ended sharply higher Monday to begin a holiday-shortened trading week, with investors increasingly confident the Federal Reserve will cut interest rates at its December meeting.

The U.S. government announced it has negotiated a 71% discount on Novo Nordisk’s (NVO) Ozempic and Wegovy drugs for patients in Medicare, ...

The US government said it negotiated a 71% discount on Novo Nordisk A/S’s blockbuster Ozempic and Wegovy drugs for patients ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Background: In January, Greystar was named as a defendant in an antitrust lawsuit filed by California Attorney General Rob ...

On a more positive note, Novo Nordisk reported positive results from a Phase 2 trial of its next highly promising GLP-1 ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

Medicare will announce negotiated prices for 15 high-cost drugs, impacting over 67 million beneficiaries. The Inflation ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.